Tornier B.V. Stock Downgraded (TRNX)

NEW YORK (TheStreet) -- Tornier B.V (Nasdaq:TRNX) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share.

• ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Highlights from the ratings report include:

• The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income has significantly decreased by 77.2% when compared to the same quarter one year ago, falling from -$2.87 million to -$5.08 million.
• Net operating cash flow has decreased to $4.48 million or 18.79% when compared to the same quarter last year. In addition, when comparing the cash generation rate to the industry average, the firm's growth is significantly lower.
• The share price of TORNIER NV has not done very well: it is down 10.71% and has underperformed the S&P 500, in part reflecting the company's sharply declining earnings per share when compared to the year-earlier quarter. The fact that the stock is now selling for less than others in its industry in relation to its current earnings is not reason enough to justify a buy rating at this time.
• TORNIER NV has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past year. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, TORNIER NV reported poor results of -$0.79 versus -$0.76 in the prior year. This year, the market expects an improvement in earnings (-$0.09 versus -$0.79).
• Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, TORNIER NV's return on equity significantly trails that of both the industry average and the S&P 500.

Tornier N.V., a medical device company, designs, manufactures, and markets devices for joint replacement and soft tissue repair that enable surgical specialists to enhance patients' lives by restoring motion and physical vitality. Tornier B.V has a market cap of $867.7 million and is part of the health care sector and health services industry. Shares are up 21.8% year to date as of the close of trading on Wednesday.

You can view the full Tornier B.V Ratings Report or get investment ideas from our investment research center.

-- Written by a member of TheStreet Ratings Staff

TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

 

For more information on Tornier B.V. click any of the following:

• Tornier B.V. Stock Price

• Tornier B.V. Analyst Ratings

• Tornier B.V. Key Stats & Profile

• Tornier B.V. Earnings

• Tornier B.V. Ratio Comparison

• Tornier B.V. Growth Rates

• Tornier B.V. Balance Sheet

• Tornier B.V. Cash Flow

• Tornier B.V. Income Statement